TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Quarantine and isolation (CDC)
- Outcomes before and after Omicron (medRxiv)
- Infectious viral load in Delta vs Omicron infections (medRxiv)
- PCR vs rapid antigen test (medRxiv)
- Booster interval to 5 months (FDA)
- Cross-reactive memory T cells (Nat Comm)
- Risk factors for severe outcomes in vaccinated (MMWR)
- Vaccine effectiveness vs MIS-C (MMWR)
- Cross-reactive T cells to Omicron from vaccines (medRxiv)
- Rivaroxiban for thromboprophylaxis (Lancet)
- Letters read on TWiV 853
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology